[Anti-streptococcal esterase (ASE) and ASO in streptococcal infections in children].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to K Mikuni.
Explore the source record for details and available documents.
Clinical trials of KS-R1 have been carried out on 28 infections in children, including 8 pharyngitis, 11 tonsillitis, a pharyngolaryngobronchitis, 3 lymphadenitis and 5 urinary tract infections. The following results were obtained. KS-R1 30-50 mg/kg/day, was clinically effective in 27 out of 28 infections. Bacteriologically, the following routine clinical isolates were identified; Enterococci in 1 case, S. viridans 1 case, S. pneumoniae 1 case, S. pyogenes 2 cases, H. parainfluenzae 1 case, E. coli 5 cases and S. aureus + H. influenzae 1 case. Every isolated organism showed +++ sensitivity to the ABPC sensitivity disc in vitro without only 1 case of E. coli. The organisms were eradicated in 11 patients after the administration of KS-R1. Adverse effects did not occur in any patient without case 25, who complained of pollakiuria.
Clinical studies of cefpiramide (CPM), a newly developed cephem antibiotic, were performed in 10 children with respiratory tract infection in 4 cases, acute enteritis in 2 cases and urinary tract infection in 4 cases aged from 2 months to 10 years and 4 months. CPM was intravenously given to patients at doses of 16 approximately 58 mg/kg/day divided into 3 times for 3 approximately 22 days. Clinical effects were excellent in 6, good in 3 and fair in 1. Bacteriologically, 3 strains of pathogenic organisms (Salmonella C2 group, E. coli and S. faecalis) isolated from the patients were eradicated with the treatment of CPM. No side effect was observed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.